Acadia Pharmaceuticals Inc. ACAD
18.32 USD -0.35 (-1.87%)
Regular-session close
18.32 0.00 0.00%
After hours · Nov 17, 5:25 PM ET
17.94 Day range 18.73
15.86 52-week range 30.96
- YTD
- -31.41%
- 1 year
- -23.70%
Benzinga news
benzinga.com Acadia Pharma Presents Additional Data From Phase 2 RADIANT Trial Evaluating Remlifanserin For Treatment Of Hallucinations And Delusions Associated With ADP, At 2026 CTAD Conference − New analyses show a consistent efficacy signal with once-daily 60 mg remlifanserin across multiple measures of psychosis, with larger estimated treatment effects with increasing baseline psychosis…
benzinga.com Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.benzinga.com Morgan Stanley Maintains Equal-Weight on Acadia Pharmaceuticals, Lowers Price Target to $24 Morgan Stanley analyst Jeffrey Hung maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and lowers the price target from $28 to $24.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…benzinga.com Canaccord Genuity Maintains Buy on Acadia Pharmaceuticals, Raises Price Target to $38 Canaccord Genuity analyst Sumant Kulkarni maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $36 to $38.
benzinga.com DraftKings Posts Downbeat Q3 Results, Joins Atlassian, Natera And Other Big Stocks Moving Lower In Friday’s Pre-Market Session Stock futures mixed as DraftKings plunged 21% after earnings missed estimates and FY26 guidance was cut; several other stocks also fell premarket.benzinga.com RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Raises Price Target to $38 RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $36 to $38.
benzinga.com ACADIA Pharmaceuticals Q3 2026 Earnings Call Transcript ACADIA Pharmaceuticals (NASDAQ:ACAD) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com ACADIA Pharmaceuticals Narrows FY2026 Sales Guidance from $1.240B-$1.300B to $1.265B-$1.295B vs $1.272B Est ACADIA Pharmaceuticals (NASDAQ:ACAD) narrows FY2026 sales outlook from $1.240 billion-$1.300 billion to $1.265 billion-$1.295 billion vs $1.272 billion estimate.
benzinga.com Needham Reiterates Buy on Acadia Pharmaceuticals, Maintains $35 Price Target Needham analyst Ami Fadia reiterates Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $35 price target.
